CNC
"Centene withdrew guidance after a $1.8B risk adjustment shortfall and its stock fell 75% from highs. With OBBBA threatening millions of Medicaid members, is the $3 EPS recovery story credible or wishful thinking?"
Centene is the largest Medicaid managed care organization in the U.S., serving 27 million members across all 50 states. In July 2025, the company withdrew FY2025 guidance after discovering a $1.8B ACA risk adjustment revenue shortfall, triggering a 40% single-day stock decline and a securities class action. FY2025 adjusted EPS collapsed to $2.08 from $6.86 the prior year. Now facing simultaneous headwinds across all business segments, management frames 2026 as a deliberate 'reset year' with EPS guidance of at least $3.00.
Executive Summary
Cross-lens roll-up assessment
Centene faces a convergence of structural headwinds across all three business segments simultaneously. The ACA Marketplace is deliberately contracting after a $1.8B risk adjustment failure. Medicaid membership is declining amid inadequate state rates and approaching OBBBA work requirements. FY2025 adjusted EPS collapsed 70% to $2.08, Q4 saw a $1.1B net loss, and the company faces a securities class action. Management's 'reset year' narrative hinges on execution capabilities that were severely tested in 2025.
Multi-vector regulatory pressure (OBBBA, ACA subsidy expiration, securities litigation), impaired management credibility (guidance withdrawal, $1.8B model failure), and financial stress across all segments warrant elevated scrutiny. Not AVOID because Medicaid managed care is a durable market and Centene's scale provides competitive resilience, but the combination of structural headwinds and execution risk creates above-normal uncertainty. The path to recovery is plausible but narrow.
Key Takeaways
- •FY2025 adjusted diluted EPS of $2.08 vs $6.86 prior year (70% decline); GAAP diluted EPS of ($2.16) vs +$3.35 — the first full-year GAAP loss
- •$1.8B ACA risk adjustment revenue shortfall across 22 of 29 states (72% of Marketplace) revealed systemic actuarial model failure, not an isolated error
- •Revenue guidance of $170-174B for 2026 represents a 12% decline from $194.8B — unprecedented for a top-5 MCO, driven by deliberate ACA contraction (5.5M to 3.5M members) and Medicaid membership decline
- •OBBBA Medicaid work requirements effective January 2027 could remove 5.3 million from Medicaid nationally; Centene as largest Medicaid MCO bears proportional exposure
- •Q4 2025 HBR of 94.3% (vs 89.6% year-ago) indicates medical costs severely outpacing premium revenue; 2026 guidance assumes 300bps improvement to 88.3-88.5%
- •Securities class action (Lunstrum v. Centene) alleges misleading statements about enrollment and morbidity; SEC reportedly reviewing risk adjustment liabilities
Key Tensions
- •Revenue classified FRAGILE by Gravy Gauge but Moat Mapper says scale advantage persists — the question is whether moat strength enables recovery or merely slows decline
- •Regulatory Reader classifies exposure as EXISTENTIAL while Gravy Gauge says ELEVATED — the difference is whether policy contraction permanently shrinks the addressable market or temporarily compresses margins
- •Management frames 2026 as a 'reset year' with $3 EPS guidance, but the same management withdrew guidance entirely in July 2025 after missing the risk adjustment shortfall — credibility is impaired
Gravy Gauge
Is this revenue durable?
Key Metrics
Key FindingsClick to expand details
Signal AssessmentsClick for full context
| Signal | Scale | Assessment | Evidence |
|---|---|---|---|
Revenue Durability | — | FRAGILE | 3Triangulated |
Regulatory Exposure | — | ELEVATED | 3Triangulated |
Model Debates
Cross-Lens Insights
Where Lenses Agree
- Revenue under multi-vector pressure across all segments simultaneously
- Regulatory compression is structural, not cyclical — driven by enacted legislation
- Management credibility impaired by guidance withdrawal and $1.8B model failure
Where Lenses Differ
REGULATORY_EXPOSURE
The Gravy Gauge sees regulatory pressure as severe margin compression within a persistent market. The Regulatory Reader sees it as structural market shrinkage. Both are defensible — the difference is whether the Medicaid MCO market ultimately absorbs policy changes (ELEVATED) or is permanently diminished (EXISTENTIAL).
The following publicly available documents were collected and extracted into a structured fact dossier that powered this analysis.
SEC Filing
- Annual Report (10-K) — FY2025
- Quarterly Reports (10-Q) — Q1-Q3 2025, Q3 2024
- Current Reports (8-K) — Including Q4 2025 Earnings
- Proxy Supplement (DEFA14A) — March 2025
- Form 4 Insider Transactions — 20 Most Recent
Earnings Transcript
- Q4 2025 Earnings Call Transcript
- Q3 2025 Earnings Call Transcript
- Q2 2025 Earnings Call Transcript
- Q1 2025 Earnings Call Transcript